FRED HUTCHINSON CANCER RESEARCH CENTER 
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE 
DEPARTMENT OF MEDICINE, DIVISION OF ONCOLOGY 
Consent to Participate in the Use of Recombinant EL-3 Stimulated Blood Progenitor Cell 
Supplementation in Autologous Bone Marrow Transplants for Patients with Breast Cancer or Hodgkin 
Disease 
Principal Investigator John Nemunaitis, M.D., Acting Assistant Professor, UW 
(764-2278); Associates: Jack Singer, M.D., Professor of Medicine, UW, Member, FHCRC; F.R. 
Appelbaum, M.D., Professor of Medicine, UW, Member, FHCRC (667-4412); C.D. Buckner, MLD., 
Professor of Medicine, UW, Member, FHCRC (667-4324); Claudio Anasetti, M.D., Assistant Member, 
FHCRC; Finn Bo Petersen, M.D., Assistant Member, FHCRC; William Bensinger, M.D., Associate 
Professor of Medicine, UW; R. Andrews, M.D., Assistant Professor of Pediatrics, UW; Keith Sullivan, 
M.D., Associate Professor of Medicine, UW; Rainer Storb, M.D., Professor of Medicine, UW, Member, 
FHCRC; E.D. Thomas, M.D., Professor of Medicine, Member, FHCRC (667-4329); John Hansen, 
M.D., Professor of Medicine, UW, Member, FHCRC (667-5511) 
Emergency (24 hour) phone: 667-5001 
Study Nurse: 583-1986 
Attending Physician: 
Phone: 
BACKGROUND 
The bone marrow is responsible for producing red blood cells, white blood cells and platelets. White 
cells are the part of the blood which are most effective in fighting infections. Following bone marrow 
transplantation (BMT), the patient’s white cell count is low. If engraftment is delayed or fails, the 
patient has an increased risk for developing serious infections, which can be fataL Antibiotics and 
isolation techniques have been used to help patients minimize infections. However, these techniques 
are only rarely successful 
Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is a protein which 
can be given to stimulate earlier recovery of blood counts, but the period of low white cell counts can 
still last 2 weeks or longer, and the period of low platelet counts can last 3-4 weeks. Recombinant 
human interleukin-3 or rhIL-3 is an investigational drug. Results from the use of rhIL-3 in healthy 
animals and preliminary human trials suggests that the rhIL-3 has been well tolerated and significantly 
enhances white cell and platelet growth. Preliminary human trials suggest that the addition of rhIL-3 
stimulated blood cells to marrow may substantially shorten the time to engraftment In addition, there 
is evidence that when used together, rhGM-CSF and rhIL-3 may be more effective than either agent 
alone in increasing recovery of blood cells after transplant 
[338] 
Recombinant DNA Research, Volume 16 
